Friday, July 10, 2026

pharma · Mantle Cell Lymphoma · Colon cancer

Telethon Foundation

Fondazione Telethon ETS is a pharma organization headquartered in EU. Primary therapeutic focus areas include Mantle Cell Lymphoma, Colon cancer, colorectal cancer, NSCLC non-small cell lung cancer, Follicular lymphoma.

roma, IT HQ
1990 Founded
343 Employees
EMA registrant Type
Company details
Status
Public
HQ
roma, IT
Founded
1990
Employees
343
Programs
162
Drugs
285
Patents
0
Clinical program

ALL3024

Phase 2 · small molecule · Very High-Risk T-Lineage Acute Lymphoblastic Leukemia (ALL)

ALL3024 for Very High-Risk T-Lineage Acute Lymphoblastic Leukemia (ALL) is a Phase 2 program (small_molecule) at Fondazione Telethon ETS with 1 ClinicalTrials.gov record(s).

← All Fondazione Telethon ETS projects Phase 2 small molecule active

Internal code ALL3024

Full intelligence profile for this program is being prepared.

At a glance

Sponsor
Fondazione Telethon ETS
Phase
Phase 2
Modality
small_molecule
Indication
Very High-Risk T-Lineage Acute Lymphoblastic Leukemia (ALL)
Status
active
Trials
1